These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6776381)

  • 1. [Treatment of advanced prostatic carcinoma using polyestradiol phosphate (Estradurin)].
    Bülow H
    Med Welt; 1980 Aug; 31(34):1215-7. PubMed ID: 6776381
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term effects of endocrine treatment on serum steroids in advanced prostatic carcinoma patients.
    Lukkarinen O; Hammond GL; Kontturi M; Vihko R
    Invest Urol; 1980 Jan; 17(4):328-31. PubMed ID: 6444293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyestradiol phosphate and ethinyl estradiol in treatment of prostatic carcinoma.
    Lindstedt E
    Scand J Urol Nephrol Suppl; 1980; 55():95-7. PubMed ID: 6938044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estract in advanced prostatic carcinoma.
    Alfthan OS; Rusk J
    Ann Chir Gynaecol Fenn; 1969; 58(3):234-40. PubMed ID: 5380304
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
    Kalland T; Haukaas S
    Invest Urol; 1981 May; 18(8):437-9. PubMed ID: 7228576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group.
    Aro J; Ruutu M; Juusela H; Hansson E; Permi J
    Ann Chir Gynaecol Suppl; 1993; 206():5-8. PubMed ID: 8291869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium.
    Mikkola A; Ruutu M; Aro J; Rannikko S; Salo J
    Ann Chir Gynaecol; 1999; 88(1):18-21. PubMed ID: 10230677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [ESTROGEN-INDUCED CHANGES IN PROSTATE PATIENTS. PHYSICAL AND MENTAL EFFECTS IN 29 PATIENTS TREATED WITH ESTRADURIN-POLYESTRADIOL PHOSPHATE].
    PETERSEN P; ZINGG E
    Urol Int; 1965; 19():317-25. PubMed ID: 14316549
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin) in prostatic cancer patients.
    Stege R; Gunnarsson PO; Johansson CJ; Olsson P; Pousette A; Carlström K
    Prostate; 1996 May; 28(5):307-10. PubMed ID: 8610057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy of prostatic carcinoma and follow-up control (II)].
    Alken CE; Dhom G; Straube W; Schmidt-Hermes HJ; Moormann JG; Moeller JF
    Urologe A; 1973 Jul; 12(4):191-7. PubMed ID: 4726451
    [No Abstract]   [Full Text] [Related]  

  • 11. Plasma concentrations of estradiol and testosterone in single-drug polyestradiol phosphate therapy for prostatic cancer.
    Norlén BJ; Fritjofsson A; Grönquist L; Gunnarsson PO; Johansson SA; Plym-Forshell G
    Eur Urol; 1987; 13(3):193-7. PubMed ID: 3609099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experience in surgical measures and supplementary treatment of proscatic carcinoma using Estradurin and Estracyt].
    Loenicker EM; Kleckner M; Reuter HJ
    ZFA (Stuttgart); 1976 Nov; 52(31):1624-6. PubMed ID: 997763
    [No Abstract]   [Full Text] [Related]  

  • 13. Cancer of the prostate; further observations with estradurin (polyestradiol phosphate).
    GOODHOPE CD
    Postgrad Semin Am Urol Assoc North Cent; 1957; ():170-1. PubMed ID: 13554425
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of prostatic carcinoma with polyestradiol phosphate combined with ethinylestradiol.
    Jönsson G
    Scand J Urol Nephrol; 1971; 5(2):97-102. PubMed ID: 5093112
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical observation of polyestradiol phosphate (estradurin) in treatment of prostatic carcinoma.
    MOOKINI RK; KELLY EF
    J Urol; 1960 Jan; 83():72-3. PubMed ID: 14423802
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate.
    Henriksson P; Eriksson A; Stege R; Collste L; Pousette A; von Schoultz B; Carlström K
    Prostate; 1988; 13(3):257-61. PubMed ID: 3211807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
    Hedlund PO; Damber JE; Hagerman I; Haukaas S; Henriksson P; Iversen P; Johansson R; Klarskov P; Lundbeck F; Rasmussen F; Varenhorst E; Viitanen J;
    Scand J Urol Nephrol; 2008; 42(3):220-9. PubMed ID: 18432528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Endocrine treatment of prostatic cancer. A renaissance for parenteral estrogen].
    Stege R; Sander S
    Tidsskr Nor Laegeforen; 1993 Mar; 113(7):833-5. PubMed ID: 8480286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy.
    Mikkola A; Aro J; Rannikko S; Ruutu M;
    Prostate; 2007 Mar; 67(4):447-55. PubMed ID: 17219379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Polyestradiol phosphate (estradurin) in prostate carcinoma].
    ZUERCHER P
    Helv Chir Acta; 1960 Oct; 27():500-5. PubMed ID: 13788928
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.